FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2140465571> ?p ?o ?g. }

• W2140465571 endingPage "7" @default.
• W2140465571 startingPage "1560" @default.
• W2140465571 abstract "Suboptimal activation of T lymphocytes by tumor cells may contribute to the failure of the immune system to control tumor growth. We recently demonstrated that Melan-A/MART-1-reactive CTLs can be anergized by peptide analogues with partial agonist/antagonist functions, which selectively impair interleukin (IL)-2 release. Here we analyze the potential expression of partial agonist/antagonist peptides by tumor cells and their role in suboptimal T-cell activation. HLA-bound peptide fractions were eluted from HLA-A*0201/Melan-A/MART-1(+) melanoma cells and analyzed for reconstitution of the MART-1-specific T-cell epitope. Among the peptide fractions able to induce IFN-gamma release by MART-1-specific T cells, only fraction 43-44 activated IL-2 production by anti-MART-1 T cells, whereas the remaining two fractions acted as peptide antagonists by inhibiting IL-2 release in response to the native epitope. A comparable down-modulation of IL-2 release could also be induced by the MART-1-derived peptide 32-40, previously identified in one of the two anergizing fractions. A substantial deficit in IL-2 release was additionally detected in tumor-specific CD8(+) T cells infiltrating melanoma lesions. To overcome IL-2 impairment by peptide antagonists, anti-MART-1 T cells were generated by in vitro sensitization with the two optimized analogues Melan-A/MART-1(27-35) 1L (with superagonist features) and Melan-A/MART-1(26-35) 2L (with improved HLA-A*0201 binding). T cells raised with the superagonist Melan-A/MART-1(27-35) 1L showed resistance to the inhibition of IL-2 release mediated by melanoma-derived peptide fractions, whereas Melan-A/MART-1(26-35) 2L-specific T cells appeared to be as sensitive as T cells raised with the parental epitope. This resistance was associated with the enhanced ability of Melan-A/MART-1(27-35) 1L-specific T cells to release IL-2. Taken together, these data indicate that melanoma cells can process and present on their surface peptides inhibiting optimal T-cell activation against immunodominant epitopes and that the usage of optimized peptide analogues could represent a promising approach for overcoming tumor-induced immunosuppression and possibly designing more successful vaccines for cancer patients." @default.
• W2140465571 created "2016-06-24" @default.
• W2140465571 creator A5001474540 @default.
• W2140465571 creator A5012911614 @default.
• W2140465571 creator A5018481533 @default.
• W2140465571 creator A5062210857 @default.
• W2140465571 creator A5066838580 @default.
• W2140465571 creator A5067882748 @default.
• W2140465571 creator A5069765350 @default.
• W2140465571 creator A5083861731 @default.
• W2140465571 creator A5090212725 @default.
• W2140465571 date "2003-04-01" @default.
• W2140465571 modified "2023-09-29" @default.
• W2140465571 title "Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues." @default.
• W2140465571 cites W1509731174 @default.
• W2140465571 cites W1572267688 @default.
• W2140465571 cites W1599999513 @default.
• W2140465571 cites W1811861207 @default.
• W2140465571 cites W1932934724 @default.
• W2140465571 cites W1983806918 @default.
• W2140465571 cites W1985149018 @default.
• W2140465571 cites W1985222144 @default.
• W2140465571 cites W1992847016 @default.
• W2140465571 cites W1995668947 @default.
• W2140465571 cites W2002806742 @default.
• W2140465571 cites W2015737099 @default.
• W2140465571 cites W2022397181 @default.
• W2140465571 cites W2030082674 @default.
• W2140465571 cites W2035960239 @default.
• W2140465571 cites W2041010325 @default.
• W2140465571 cites W2045642969 @default.
• W2140465571 cites W2060264122 @default.
• W2140465571 cites W2090177390 @default.
• W2140465571 cites W2096290400 @default.
• W2140465571 cites W2099417663 @default.
• W2140465571 cites W2099735866 @default.
• W2140465571 cites W2104401164 @default.
• W2140465571 cites W2107208338 @default.
• W2140465571 cites W2109779279 @default.
• W2140465571 cites W2110932366 @default.
• W2140465571 cites W2118600639 @default.
• W2140465571 cites W2125513235 @default.
• W2140465571 cites W2125757318 @default.
• W2140465571 cites W2127525056 @default.
• W2140465571 cites W2130185552 @default.
• W2140465571 cites W2132207342 @default.
• W2140465571 cites W2132680012 @default.
• W2140465571 cites W2144223273 @default.
• W2140465571 cites W2144584970 @default.
• W2140465571 cites W2161650475 @default.
• W2140465571 cites W2164733883 @default.
• W2140465571 cites W2167008563 @default.
• W2140465571 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12670905" @default.
• W2140465571 hasPublicationYear "2003" @default.
• W2140465571 type Work @default.
• W2140465571 sameAs 2140465571 @default.
• W2140465571 citedByCount "13" @default.
• W2140465571 countsByYear W21404655712012 @default.
• W2140465571 countsByYear W21404655712013 @default.
• W2140465571 countsByYear W21404655712019 @default.
• W2140465571 countsByYear W21404655712020 @default.
• W2140465571 countsByYear W21404655712023 @default.
• W2140465571 crossrefType "journal-article" @default.
• W2140465571 hasAuthorship W2140465571A5001474540 @default.
• W2140465571 hasAuthorship W2140465571A5012911614 @default.
• W2140465571 hasAuthorship W2140465571A5018481533 @default.
• W2140465571 hasAuthorship W2140465571A5062210857 @default.
• W2140465571 hasAuthorship W2140465571A5066838580 @default.
• W2140465571 hasAuthorship W2140465571A5067882748 @default.
• W2140465571 hasAuthorship W2140465571A5069765350 @default.
• W2140465571 hasAuthorship W2140465571A5083861731 @default.
• W2140465571 hasAuthorship W2140465571A5090212725 @default.
• W2140465571 hasConcept C147483822 @default.
• W2140465571 hasConcept C153911025 @default.
• W2140465571 hasConcept C154317977 @default.
• W2140465571 hasConcept C167672396 @default.
• W2140465571 hasConcept C170493617 @default.
• W2140465571 hasConcept C185592680 @default.
• W2140465571 hasConcept C195616568 @default.
• W2140465571 hasConcept C202751555 @default.
• W2140465571 hasConcept C203014093 @default.
• W2140465571 hasConcept C2776090121 @default.
• W2140465571 hasConcept C2778938600 @default.
• W2140465571 hasConcept C2779281246 @default.
• W2140465571 hasConcept C55493867 @default.
• W2140465571 hasConcept C86803240 @default.
• W2140465571 hasConcept C8891405 @default.
• W2140465571 hasConceptScore W2140465571C147483822 @default.
• W2140465571 hasConceptScore W2140465571C153911025 @default.
• W2140465571 hasConceptScore W2140465571C154317977 @default.
• W2140465571 hasConceptScore W2140465571C167672396 @default.
• W2140465571 hasConceptScore W2140465571C170493617 @default.
• W2140465571 hasConceptScore W2140465571C185592680 @default.
• W2140465571 hasConceptScore W2140465571C195616568 @default.
• W2140465571 hasConceptScore W2140465571C202751555 @default.
• W2140465571 hasConceptScore W2140465571C203014093 @default.
• W2140465571 hasConceptScore W2140465571C2776090121 @default.
• W2140465571 hasConceptScore W2140465571C2778938600 @default.

• next